Testing PA5 in advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called PA5 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if PA5 is safe and how well it works against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have an advanced solid tumor (cancer that has spread or cannot be removed) that has not responded to or cannot have standard treatments
- You are able to do most of your daily activities without help (ECOG score 0 or 1)
- You have not had a severe allergic reaction to polyethylene glycol (PEG)
- You have not been treated with ADI-PEG20 or a similar drug before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, PE0116 and PE0105, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the combination is safe and effective for cancers like kidney, head and neck, cervical, or ovarian cancer.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.